Last 12 months
Inside the activity.
0 purchase rows · 6 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2015 Filed Mar 3, 2015 23:07 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
SaleCommon stock, $0.01 par value | 2,074 | $60.51 | $125,491.52 |
DisclosureSEC source: 0001179110-15-004096 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,860 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 23:07 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
Tax withholdingCommon stock, $0.01 par value | 6,128 | $60.52 | $370,866.56 |
DisclosureSEC source: 0001179110-15-004096 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,934 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 23:09 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
SaleCommon stock, $0.01 par value | 2,112 | $60.47 | $127,706.30 |
DisclosureSEC source: 0001179110-15-004097 · edgar.xml · nonDerivative · entry 2 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,555 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 23:09 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Tax withholdingCommon stock, $0.01 par value | 5,901 | $60.52 | $357,128.52 |
DisclosureSEC source: 0001179110-15-004097 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,667 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 23:10 UTC |
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC
|
Tax withholdingCommon stock, $0.01 par value | 17,584 | $60.52 | $1,064,183.68 |
DisclosureSEC source: 0001179110-15-004098 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,433 Read SEC document |
| February 27, 2015 Filed Mar 3, 2015 18:15 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
Tax withholdingCommon stock, $0.01 par value | 43,784 | $60.52 | $2,649,807.68 |
DisclosureSEC source: 0001179110-15-004100 · edgar.xml · nonDerivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,972 Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:07 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantOption (right to buy) · Derivative | 101,960 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003160 · edgar.xml · derivative · entry 3 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,960 Underlying: Common stock · 101,960 shares Expires 2025-02-18 F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 33,987 on 02/19/2016, 33,986 on 02/19/2017, and 33,987 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:07 UTC |
ALBAN CARLOSEVP, Commercial Operations
|
GrantCommon stock, $0.01 par value | 51,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003160 · edgar.xml · nonDerivative · entry 1 ALBAN CARLOS · CIK 0001474632 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,718 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:08 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantOption (right to buy) · Derivative | 110,770 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003161 · edgar.xml · derivative · entry 3 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,770 Underlying: Common stock · 110,770 shares Expires 2025-02-18 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 36,924 on 02/19/2016, 36,923 on 02/19/2017, and 36,923 on 02/18/2018 Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:08 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
GrantCommon stock, $0.01 par value | 56,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003161 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,519 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. F2 · balance_after: The amount of securities beneficially owned by the reporting person includes an additional 411 shares of AbbVie stock. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 17:09 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantOption (right to buy) · Derivative | 327,290 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003162 · edgar.xml · derivative · entry 2 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,290 Underlying: Common stock · 327,290 shares Expires 2025-02-18 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 109,097 on 02/19/2016, 109,096 on 02/19/2017, and 109,097 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 17:09 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GrantCommon stock, $0.01 par value | 165,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003162 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,918 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:10 UTC |
HURWICH THOMAS A.VP, Controller
|
GrantOption (right to buy) · Derivative | 21,390 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003163 · edgar.xml · derivative · entry 4 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,390 Underlying: Common stock · 21,390 shares Expires 2025-02-18 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 7,130 on 02/19/2016, 7,130 on 02/19/2017, and 7,130 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:10 UTC |
HURWICH THOMAS A.VP, Controller
|
GrantCommon stock, $0.01 par value | 10,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003163 · edgar.xml · nonDerivative · entry 1 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,031 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:11 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantOption (right to buy) · Derivative | 50,350 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003164 · edgar.xml · derivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,350 Underlying: Common stock · 50,350 shares Expires 2025-02-18 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 16,784 on 02/19/2016, 16,783 on 02/19/2017, and 16,783 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:11 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
GrantCommon stock, $0.01 par value | 25,470 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003164 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,062 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:11 UTC |
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC
|
GrantOption (right to buy) · Derivative | 103,220 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003165 · edgar.xml · derivative · entry 2 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,220 Underlying: Common stock · 103,220 shares Expires 2025-02-18 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exerciseable in annual increments of 34,407 on 02/19/2016, 34,406 on 02/19/2017, and 34,407 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:11 UTC |
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC
|
GrantCommon stock, $0.01 par value | 52,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003165 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,017 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:12 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantOption (right to buy) · Derivative | 52,870 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003166 · edgar.xml · derivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,870 Underlying: Common stock · 52,870 shares Expires 2025-02-18 F4 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exerciseable in annual increments of 17,624 on 02/19/2016, 17,623 on 02/19/2017, and 17,623 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:12 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
GrantCommon stock, $0.01 par value | 26,740 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003166 · edgar.xml · nonDerivative · entry 1 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,568 F1 · shares: These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:13 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantOption (right to buy) · Derivative | 104,480 | $0.00 Strike: $58.88 | $0.00 |
DisclosureSEC source: 0001179110-15-003167 · edgar.xml · derivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,480 Underlying: Common stock · 104,480 shares Expires 2025-02-18 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 34,827 on 02/19/2016, 34,826 on 02/19/2017, and 34,826 on 02/19/2018. Read SEC document |
| February 19, 2015 Filed Feb 23, 2015 22:13 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantCommon stock, $0.01 par value | 52,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-003167 · edgar.xml · nonDerivative · entry 1 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,485 F1 · shares: This stock represents performance vested restricted stock under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have a stock withheld for tax purposes. Read SEC document |
| February 17, 2015 Filed Feb 19, 2015 22:51 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
SaleCommon stock, $0.01 par value | 241 | $58.70 | $14,146.94 |
DisclosureSEC source: 0001179110-15-002972 · edgar.xml · nonDerivative · entry 2 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,592 Read SEC document |
| February 17, 2015 Filed Feb 19, 2015 22:51 UTC |
RICHMOND TIMOTHY J.SVP, Human Resources
|
Tax withholdingCommon stock, $0.01 par value | 551 | $58.05 | $31,985.55 |
DisclosureSEC source: 0001179110-15-002972 · edgar.xml · nonDerivative · entry 1 RICHMOND TIMOTHY J. · CIK 0001563523 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,833 Read SEC document |
| February 09, 2015 Filed Feb 11, 2015 22:28 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Exercise / conversionOption (right to buy) · Derivative | 2,250 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001179110-15-002333 · edgar.xml · derivative · entry 5 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common stock · 2,250 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2015 Filed Feb 11, 2015 22:28 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Tax withholdingCommon stock, $0.01 par value | 1,425 | $56.90 | $81,082.50 |
DisclosureSEC source: 0001179110-15-002333 · edgar.xml · nonDerivative · entry 4 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 1,743 F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by her spouse. Read SEC document |
| February 09, 2015 Filed Feb 11, 2015 22:28 UTC |
SALEKI-GERHARDT AZITASVP, Operations
|
Exercise / conversionCommon stock, $0.01 par value | 2,250 | $24.07 | $54,164.48 |
DisclosureSEC source: 0001179110-15-002333 · edgar.xml · nonDerivative · entry 3 SALEKI-GERHARDT AZITA · CIK 0001563545 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 3,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The reporting person disclaims beneficial ownership of all securities held by her spouse. Read SEC document |
| February 04, 2015 Filed Mar 3, 2015 18:15 UTC |
GONZALEZ RICHARD ADirector · Chairman of the Board and CEO
|
GiftCommon stock, $0.01 par value | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-004100 · edgar.xml · nonDerivative · entry 1 GONZALEZ RICHARD A · CIK 0001239127 · Director · Chairman of the Board and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,756 F1 · balance_after: Reflects the transfer of 1,238 shares of AbbVie stock that was exempt from Section 16. Read SEC document |
| December 31, 2014 Filed Jan 5, 2015 22:27 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 120 | $65.44 Strike: $0.00 | $7,852.80 |
DisclosureSEC source: 0001179110-15-000285 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,887 Underlying: Common Stock · 120 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2014 Filed Jan 5, 2015 17:27 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 527 | $65.44 Strike: $0.00 | $34,486.88 |
DisclosureSEC source: 0001179110-15-000288 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,963 Underlying: Common stock · 527 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend equivalent reinvestment feature. Read SEC document |
| December 31, 2014 Filed Jan 5, 2015 22:28 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 504 | $65.44 Strike: $0.00 | $32,981.76 |
DisclosureSEC source: 0001179110-15-000292 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,432 Underlying: Common Stock · 504 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2014 Filed Jan 5, 2015 17:29 UTC |
TILTON GLENN FDirector
|
GrantStock Equivalent Units · Derivative | 527 | $65.44 Strike: $0.00 | $34,486.88 |
DisclosureSEC source: 0001179110-15-000295 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,068 Underlying: Common Stock · 527 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 22, 2014 Filed Dec 22, 2014 22:22 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
Exercise / conversionOption (right to buy) · Derivative | 8,495 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001179110-14-018635 · edgar.xml · derivative · entry 4 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 8,495 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2014 Filed Dec 22, 2014 22:22 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
SaleCommon stock, $0.01 par value | 8,495 | $68.00 | $577,660.00 |
DisclosureSEC source: 0001179110-14-018635 · edgar.xml · nonDerivative · entry 2 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,068 Read SEC document |
| December 22, 2014 Filed Dec 22, 2014 22:22 UTC |
CHASE WILLIAM JEVP, Chief Financial Officer
|
Exercise / conversionCommon stock, $0.01 par value | 8,495 | $24.07 | $204,500.98 |
DisclosureSEC source: 0001179110-14-018635 · edgar.xml · nonDerivative · entry 1 CHASE WILLIAM J · CIK 0001563572 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2014 Filed Nov 26, 2014 22:00 UTC |
HURWICH THOMAS A.VP, Controller
|
SaleCommon stock, $0.01 par value | 100 | $67.82 | $6,781.50 |
DisclosureSEC source: 0001179110-14-017220 · edgar.xml · nonDerivative · entry 2 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,211 Read SEC document |
| November 24, 2014 Filed Nov 26, 2014 22:00 UTC |
HURWICH THOMAS A.VP, Controller
|
SaleCommon stock, $0.01 par value | 1,400 | $67.81 | $94,935.54 |
DisclosureSEC source: 0001179110-14-017220 · edgar.xml · nonDerivative · entry 1 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,311 Read SEC document |
| November 12, 2014 Filed Nov 26, 2014 22:01 UTC |
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GC
|
GiftCommon stock, $0.01 par value | 788 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-017221 · edgar.xml · nonDerivative · entry 1 Schumacher Laura J · CIK 0001319245 · EVP, Bus.Dev.,Ext.Aff.&GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,797 Read SEC document |
| November 06, 2014 Filed Nov 7, 2014 22:57 UTC |
HURWICH THOMAS A.VP, Controller
|
Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001179110-14-016292 · edgar.xml · derivative · entry 5 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 10,000 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2014 Filed Nov 7, 2014 22:57 UTC |
HURWICH THOMAS A.VP, Controller
|
Tax withholdingCommon stock, $0.01 par value | 6,737 | $62.54 | $421,331.98 |
DisclosureSEC source: 0001179110-14-016292 · edgar.xml · nonDerivative · entry 2 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,711 Read SEC document |
| November 06, 2014 Filed Nov 7, 2014 22:57 UTC |
HURWICH THOMAS A.VP, Controller
|
Exercise / conversionCommon stock, $0.01 par value | 10,000 | $24.07 | $240,731.00 |
DisclosureSEC source: 0001179110-14-016292 · edgar.xml · nonDerivative · entry 1 HURWICH THOMAS A. · CIK 0001563573 · VP, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2014 Filed Oct 2, 2014 21:00 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 136 | $57.76 Strike: $0.00 | $7,855.36 |
DisclosureSEC source: 0001179110-14-014923 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,742 Underlying: Common Stock · 136 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2014 Filed Oct 2, 2014 17:01 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 597 | $57.76 Strike: $0.00 | $34,482.72 |
DisclosureSEC source: 0001179110-14-014929 · edgar.xml · derivative · entry 1 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,361 Underlying: Common stock · 597 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend equivalent reinvestment feature. Read SEC document |
| September 30, 2014 Filed Oct 2, 2014 21:02 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 571 | $57.76 Strike: $0.00 | $32,980.96 |
DisclosureSEC source: 0001179110-14-014936 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,896 Underlying: Common Stock · 571 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| September 30, 2014 Filed Oct 2, 2014 17:03 UTC |
TILTON GLENN FDirector
|
GrantStock Equivalent Units · Derivative | 597 | $57.76 Strike: $0.00 | $34,482.72 |
DisclosureSEC source: 0001179110-14-014938 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,414 Underlying: Common Stock · 597 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2014 Filed Jul 2, 2014 21:15 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 0 | $56.44 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-011337 · edgar.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,578 Underlying: Common Stock · 139 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2014 Filed Jul 2, 2014 17:16 UTC |
LIDDY EDWARD MDirector
|
GrantStock Equivalent Units · Derivative | 611 | $56.44 Strike: $0.00 | $34,484.84 |
DisclosureSEC source: 0001179110-14-011338 · edgar.xml · derivative · entry 6 LIDDY EDWARD M · CIK 0001188983 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,681 Underlying: Common stock · 611 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend equivalent reinvestment feature. Read SEC document |
| June 30, 2014 Filed Jul 2, 2014 21:16 UTC |
RAPP EDWARD JDirector
|
GrantStock Equivalent Units · Derivative | 584 | $56.44 Strike: $0.00 | $32,960.96 |
DisclosureSEC source: 0001179110-14-011339 · edgar.xml · derivative · entry 1 RAPP EDWARD J · CIK 0001171780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,291 Underlying: Common Stock · 584 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 30, 2014 Filed Jul 2, 2014 17:17 UTC |
TILTON GLENN FDirector
|
GrantStock Equivalent Units · Derivative | 611 | $56.44 Strike: $0.00 | $34,484.84 |
DisclosureSEC source: 0001179110-14-011340 · edgar.xml · derivative · entry 1 TILTON GLENN F · CIK 0001194624 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,671 Underlying: Common Stock · 611 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| June 02, 2014 Filed Jun 4, 2014 21:51 UTC |
SEVERINO MICHAELEVP, R&D and CSO
|
GrantOption (right to buy) · Derivative | 74,309 | $0.00 Strike: $54.44 | $0.00 |
DisclosureSEC source: 0001179110-14-009765 · edgar.xml · derivative · entry 2 SEVERINO MICHAEL · CIK 0001609447 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,309 Underlying: Common stock · 74,309 shares Expires 2024-06-01 F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,770 on 06/02/2015, 24,769 on 06/02/2016, and 24,770 on 06/02/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.